5results about "Calcitonins" patented technology

Provided herein are the use of fatty acid-containing side chains in improving the activity, activity selectivity, and oral availability of polypeptide derivatives, methods for achieving such use, and polypeptide derivatives modified by such side chains.

A compound comprising a peptide chain which is an analogue of amylin, a terminal —NH2 group bound to the C terminal of the peptide chain, and an alkylene or alkenylene chain attached at the other end of the peptide chain or a derivative of the compound; or a salt or solvate of the compound or of the derivative. Compounds, derivates and salts, and related compositions are suitable for the prevention or treatment of diabetes, obesity, heart disease, stroke and non-alcoholic fatty liver disease, improving insulin release in a subject, improving carbohydrate metabolism in a subject, improving the lipid profile of a subject, improving carbohydrate tolerance in a subject, reducing appetite, reducing food intake, and / or reducing calorie intake, and related purposes.

The present invention provides a GLP-1- / GIP- / amylin-receptor tri-agonist having a balanced potency ratio across all three receptors and / or having improved pharmacokinetic properties. The invention also provides pharmaceutical compositions comprising such a GLP-1- / GIP- / amylin-receptor tri-agonist as well as their use as a medicament for the treatment of subjects with overweight, obesity and associated co-morbidity.

The present disclosure is directed to peptide immunogen constructs targeting portions of Calcitonin Gene-Related Peptide (CGRP), compositions containing the constructs, antibodies elicited by the constructs, and methods for making and using the constructs and compositions thereof. The disclosed peptide immunogen constructs have more than about 30 amino acids and contain (a) a B cell epitope having about more than about 7 contiguous amino acid residues from the CGRP receptor binding or activation regions of the full-length CGRP protein; (b) a heterologous Th epitope; and (c) an optional heterologous spacer. The disclosed CGRP peptide immunogen constructs stimulate the generation of highly specific antibodies directed CGRP for the prevention and / or treatment of migraine.

The problem that the present invention aims to solve is to provide a more effective pharmaceutical agent that is potent in vitro and effective in reducing body weight, while simultaneously not causing a proportionally increased level of side effects, possessing improved pharmacokinetic properties, improved chemical stability, and being suitable for once-weekly administration in humans and / or oral administration. [Solution] The present invention relates to a GLP-1 / GIP / amyrin receptor triple agonist having a balanced potency ratio across all three receptors and / or improved pharmacokinetic properties. The present invention also relates to pharmaceutical compositions comprising such a GLP-1 / GIP / amyrin receptor triple agonist, as well as their use as pharmaceuticals for the treatment of subjects having overweight, obesity, and associated comorbidities.